1. Терещенко С.Н. Особый подход к сердцу женщины. ХСН и β-адреноблокаторы. Сердце. 2007; 5 (14): 15–20.
2. Гуревич М.А., Мравян С.Р. Диагностика и лечение ишемической болезни сердца у женщин. Болезни сердца и сосудов. 2007; 3: 38–46.
3. American Heart Association. Guidelines to comprehensive risk reduction to patients with coronary and other vascular diseases. J Am Coll Cardiol 1995; 26: 293–5.
4. Кобалава Ж.Д., Толкачева В.В., Морылева О.Н. Клинические особенности и лечение артериальной гипертонии у женщин. Сердце. 2004; 3 (6): 284–9.
5. Castelli W. Epidemioligy of triglycerides: view from Framingbam. Am J Cardiol 1992; 70; 3H–9H.
6. Schmitz J. Smoking cessation in women with cardiac risk. Am J Med Sci 2003; 326: 192–6.
7. Верткин А., Прохорович Е., Ткачева О. Клинический смысл гендерной медицины. Мед. газета. 2006; 26. Электронная версия.
8. Marroguin O, Kip K, Kelley D et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women.A Report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109: 714–21.
9. Волков В.И., Строна В.И. Гендерные и возрастные особенности ишемической болезни сердца. Здоровая Украина 2007; 12 (1): 33–5.
10. Лякишев А.А. Особенности ишемической болезни сердца у женщин. Мед. энциклопед. 2003. Электронная версия.
11. Драпкина О.М., Дикур О.Н. Преимущества антагонистов рецепторов ангиотензина II в лечении АГ у женщин. Рус. мед. журн. 2008; 21 (16): 1462–5.
12. Ridker P, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Invest Med 1998; 46: 391–5.
13. Rossi ML, Merlini PA, Ardissino D. Percutaneous coronary revascularisation in women. Thromb Res 2001; 103: S105–111.
14. Sugimoto K, Qi NR, Kazdova L et all:Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003.
15. Kelsey SF, James M, Holubkov AL et al. Results of percutaneous transluminal coronary angioplasty in women: 1985–1986 National Heart,Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993; 87: 720–7.
16. Malenka DJ, Wennberg DE, Quinton HA et al.Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. J Am Coll Cardiol 2002; 40: 2092–101.
17. Davis KB,Chaitman B, Ryan T et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. Coronary Artery Surgery Study J Am Coll Cardiol 1995; 25: 1000–9.
18. Mendes LA, Davidoff R, Сupples LA et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997; 134: 207–12.
19. Regitz-Zagrosek V, Lehmkuhl E, Hocher B et al. Effects of female sex and age on early mortality in aortocoronary bypass surgery. Eur Heart J 2004; 25 (Abstract Supp.): 134–42.
20. Bavry AA, Kumbhani DJ, Quiroz R et al. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improver survival in non-ST segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004; 93: 830–5.
21. Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non- ST-elevation myocardial infarction:a TACTICS- TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004; 109: 580–6.
22. Tamis-Holland JE, Palazzo A, Stebbins AL et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty Angioplasty (CUSTO II-B) Angioplasty Substudy. Am Heart J 2004; 147: 133–9.
23.Wong SC, Sleeper LA, Monrad ES et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SNOCK Trial Registry. J Am Coll Cardiol 2001; 38:1395–401.
24. Devereux RB, Alonso DR, Lutas EM et al. Echocardio-graphic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–8.
25. Levy D, Anderson KM, Savage DD et. al. Echocardiofraphically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med 1988; 108: 7–13.
26. Reichek N, Helak J, Plappert T et. al. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation 1983; 67: 348–52.